Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961566 | 0.79 | SLC6A2 (0.43) | — | |
| SCHEMBL6966551 | 0.77 | METAP2 (0.43) | SMN1; SMN2 | |
| SCHEMBL6955858 | 0.77 | HRH3 (0.47) | MAOBMAOARAB9A | |
| SCHEMBL6963222 | 0.74 | METAP2 (0.44) | SMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL2208211 | 0.73 | NR1H4 (0.55) | MAOBSMN1; SMN2HPGDRAB9AABCB1 | |
| SCHEMBL2089093 | 0.72 | NR1H4 (0.56) | MAOBMAOAABCB1 | |
| SCHEMBL2087923 | 0.71 | NR1H4 (0.62) | MAOBMAOASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6961211 | 0.71 | METAP2 (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL6966902 | 0.69 | PTGDR2 (0.39) | SMN1; SMN2 | |
| SCHEMBL12952744 | 0.69 | NR1H4 (0.51) | SMN1; SMN2HPGDRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | claimed |
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | MAOB 567/4885MAOA 418/4885SMN1; SMN2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.